Back to top
more

Avanos Medical (AVNS)

(Delayed Data from NYSE)

$11.25 USD

11.25
514,700

+0.27 (2.46%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $11.29 +0.04 (0.36%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Reasons to Retain ShockWave Medical (SWAV) in Your Portfolio

by Zacks Equity Research

ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.

Zacks Equity Research

Orthofix (OFIX) Q4 Earnings Beat Estimates, Gross Margin Dips

by Zacks Equity Research

Orthofix (OFIX) reports impressive performance across the BGT and Global Orthopedics segment in the fourth quarter.

Zacks Equity Research

Nevro's (NVRO) Latest Launch to Customize Chronic Pain Treatment

by Zacks Equity Research

Nevro's (NVRO) Senza HFX iQ SCS system is expected to treat individual patients per their particular treatment requirements.

Zacks Equity Research

Here's Why You Should Retain Catalent (CTLT) Stock for Now

by Zacks Equity Research

Catalent's (CTLT) product and service launches and a slew of strategic deals raise optimism about the stock.

Zacks Equity Research

Three Reasons to Add BD (BDX) Stock to Your Portfolio Now

by Zacks Equity Research

Investors continue to be optimistic about BD (BDX) owing to a few regulatory approvals and product launches.

Zacks Equity Research

Here's Why You Should Retain Surmodics (SRDX) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Surmodics (SRDX) owing to its solid prospects in the thrombectomy business.

Zacks Equity Research

Walgreens Boots (WBA) Benefits From New Launches Amid FX Woes

by Zacks Equity Research

Walgreens Boots' (WBA) comparable pharmacy sales decline, reflecting lower demand for COVID-19 services.

Zacks Equity Research

Humana (HUM) Ties Up To Offer Value-Based Care to MA Members

by Zacks Equity Research

Humana (HUM) inks a 10-year collaboration with Aledade to ensure continued value-based primary care to its Medicare Advantage members from Aledade-backed physicians.

Zacks Equity Research

NextGen (NXGN) Behavioral Health Suite Adopted by Compass Health

by Zacks Equity Research

NextGen's (NXGN) Behavioral Health Suite is expected to aid Compass Health in improving its workflow.

Zacks Equity Research

Should Value Investors Buy Avanos Medical (AVNS) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

SmileDirectClub (SDC) Q4 Earnings Beat, Gross Margin Down

by Zacks Equity Research

SmileDirectClub (SDC) delivers an improved bottom line and cash flows in the fourth quarter despite a reduction in revenues.

Zacks Equity Research

Community Health (CYH) to Divest Two NC Hospitals for $320M

by Zacks Equity Research

Community Health (CYH) expects the North Carolina hospitals' divestment to close at a later part of this year.

Zacks Equity Research

Humana (HUM), CD&R Backed Gentiva to Buy Assets From ProMedica

by Zacks Equity Research

The acquisition is expected to boost Humana (HUM) and CD&R backed Gentiva's reach to over 500 locations.

Zacks Equity Research

Omnicell (OMCL) Q4 Earnings Beat Estimates, Margins Down

by Zacks Equity Research

Omnicell (OMCL) delivers earnings and revenues in the fourth quarter exceeding the previously revised outlook amid macroeconomic challenges.

Zacks Equity Research

Acadia Healthcare (ACHC) Q4 Earnings Miss on Rising Costs

by Zacks Equity Research

Acadia Healthcare's (ACHC) 2023 capital expenditure for expansion initiatives is predicted to stay between $350 million and $400 million.

Zacks Equity Research

Alcon (ALC) Q4 Earnings Match Estimates, Margins Contract

by Zacks Equity Research

Alcon (ALC) reports impressive CER growth in net sales across all segments in the fourth quarter amid a challenging macroeconomic environment.

Zacks Equity Research

PerkinElmer's (PKI) Latest Launch to Boost Research Workflows

by Zacks Equity Research

PerkinElmer's (PKI) latest launch is expected to provide increased assay flexibility to researchers.

Zacks Equity Research

Reasons to Add Quest Diagnostics (DGX) Stock to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Quest Diagnostics (DGX) on its accelerated growth strategy and improvements in base volumes.

Zacks Equity Research

BD's (BDX) New FDA Approval to Improve Cervical Cancer Testing

by Zacks Equity Research

BD's (BDX) receipt of the latest FDA approval is likely to improve the detection and prevention of cervical cancer.

Zacks Equity Research

What Makes Avanos Medical (AVNS) a New Buy Stock

by Zacks Equity Research

Avanos Medical (AVNS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

Avanos (AVNS) Q4 Earnings Surpass Estimates, Margins Up

by Zacks Equity Research

Avanos' (AVNS) fourth-quarter 2022 results reflect strength in both segments.

Zacks Equity Research

Avanos Medical (AVNS) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Avanos Medical (AVNS) delivered earnings and revenue surprises of 25% and 1.11%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Debanjana Dey headshot

3 Beaten-Down MedTech Stocks Poised for a Turnaround in 2023

by Debanjana Dey

Here are some dirt-cheap MedTech value stocks - DYNT, INGN, AVNS - which are expected to provide long-term gains.

Zacks Equity Research

3 Reasons to Retain Avanos (AVNS) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Avanos (AVNS) owing to its strong product line and focus on R&D.

Zacks Equity Research

Avanos Medical (AVNS) Up 21% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Avanos Medical (AVNS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.